Surprising role of gene regulator protein in development of skin tumors

November 18, 2013
Surprising role of gene regulator protein in development of skin tumors

Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) – a member of a family of chromatin modifying proteins – in the development of skin tumors. The results from Christian Seiser and his team also emphasize that care must be taken when using HDAC inhibitors as anti-cancer drugs.

Skin tumors – when healing of scratches and cuts goes wrong

The is the largest organ of the human body, protecting us from dehydration and external impacts. It's a self-renewing tissue, meaning that if we hurt ourselves for example by scraping or cutting our skin, new skin cells will replace the old damaged ones and our wound will heal. On a molecular level this process is controlled by a wide range of factors, ensuring that the right number of undifferentiated progenitor cells differentiate into skin cells and make their way to replace the old damaged ones. If something goes wrong during this process, pathologies, including skin tumors, can be the consequence. And with non-melanoma skin cancers being the most frequent human tumors, there is clearly a tremendous need to understand the underlying molecular mechanisms, to allow the development of drugs to treat these types of cancer.

Chromatin or how to fit the genomic DNA in a cell's nucleus

One regulatory mechanism known to be involved in skin development and renewal is chromatin modification. Basically, chromatin is the DNA of a cell wrapped around a barrel shaped structure of proteins – so-called histones – condensing the DNA so that it can actually fit within a cell's nucleus. The histones that form the barrels can be reversibly modified via the attachment of small chemical groups, which in turn regulates how tightly the DNA can be wrapped around them and therefore how condensed the chromatin is. This process controls which proteins are made in a cell at a given moment, also determining in the early stages of life which cells develop into muscle cells, brain cells or for example. In self-renewing tissues, such as the skin, chromatin modification is also involved in regulating the replacement of old or damaged in later stages in life.

Targeting HDACs to treat cancer

One type of chromatin modifiers is called histone deacetylase (HDAC), of which 18 variants are known in humans. HDAC inhibitors are already approved for cancer treatment but most of these drugs are not specific and act on several HDAC variants. This is a problem, as inhibiting the wrong variant can actually accelerate as the team of Christian Seiser at the MFPL and the Medical University of Vienna has now shown. In a project supported by the Austrian Genome research program GEN-AU they looked at the two variants, HDAC1 and HDAC2, which based on previous results were promising targets for tumor therapy and are known to have redundant functions. "When we ablated the function of either of these proteins in the skin of a mouse model system it had no obvious effect.

However, when we ablated HDAC1 function completely and HDAC2 function partly we saw severe developmental defects and the spontaneous development of ," explains Christian Seiser. They further investigated this phenotype in a skin tumor model system, provided by Maria Sibilia from the Institute for Cancer Research of the Medical University of Vienna, and found that deactivating HDAC1 actually accelerates tumor development, while HDAC2 deactivation has no effect.

These results came as a big surprise for the researchers, who had initially thought that deactivating or inhibiting HDAC1 would halt cancer progression, but found that in skin cancer the opposite is true. Christian Seiser says: "Our results highlight that it is crucial to understand the individual role the various HDAC variants in different cell types and hence different types of cancer, before HDAC inhibitors can be used safely as therapeutics."

Explore further: Researchers describe a new function of two molecules involved in metastasis

More information: Mircea Winter, Mirjam A Moser, Dominique Meunier, Carina Fischer, Georg Machat, Katharina Mattes, Beate M Lichtenberger, Reinhard Brunmeir, Simon Weissmann, Christina Murko, Christina Humer, Tina Meischel, Gerald Brosch, Patrick Matthias, Maria Sibilia and Christian Seiser: Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis. EMBO Journal (November 2013). DOI: 10.1038/emboj.2013.243

Related Stories

Researchers describe a new function of two molecules involved in metastasis

November 14, 2013
Researchers from IMIM (Hospital del Mar Medical Research Institute) lead by Dr. Sandra Peiró have described a new function for two key molecules involved in tumor progression. Transcription factor SNAIL1 and enzyme LOXL2 ...

Tweaking gene expression to repair lungs

February 25, 2013
A healthy lung has some capacity to regenerate itself like the liver. In COPD, these reparative mechanisms fail. HDAC therapies may be useful for COPD, as well as other airway diseases. The levels of HDAC2 expression and ...

Predicting cancer's next move

November 11, 2013
Research led by Broad senior associate member Levi Garraway and published this week in Nature offers a new approach to studying drug resistance in cancer. The approach helped them identify which biological pathways could ...

Recommended for you

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Mutant gene found to fuel cancer-promoting effects of inflammation

October 19, 2017
A human gene called p53, which is commonly known as the "guardian of the genome," is widely known to combat the formation and progression of tumors. Yet, mutant forms of p53 have been linked to more cases of human cancer ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

Breast cancer researchers find bacteria imbalance link

October 19, 2017
Researchers in the United States have uncovered differences in the bacterial composition of breast tissue of healthy women versus those with breast cancer.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.